Cargando…

Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma

INTRODUCTION: S-1, a new oral fluorouracil chemotherapeutical drug, has been increasingly used in clinical maintenance after first-line chemotherapy for stage III or IV gastric carcinoma (GC) and colorectal carcinoma (CRC) for its own advantages. XiangshaLiujunzi Decoction (XSLJZD), a classic tradit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Xiao-Cui, Liang, Qi-Lian, Luo, Xing-Bo, Hu, Ke-Hui, Yang, Hai-Xia, Ou, Wen-ting, Zhang, Hui-Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440293/ https://www.ncbi.nlm.nih.gov/pubmed/32384478 http://dx.doi.org/10.1097/MD.0000000000020081

Ejemplares similares

Chemopreventive effects of Xiang Sha Liu Jun Zi Tang on paclitaxel-induced leucopenia and neuropathy in animals
por: Shiah, Her-Shyong, et al.
Publicado: (2023)

Chinese Herbal Medicine Liu Jun Zi Tang and Xiang Sha Liu Jun Zi Tang for Functional Dyspepsia: Meta-Analysis of Randomized Controlled Trials
por: Xiao, Ya, et al.
Publicado: (2012)

A study related to the treatment of gastric cancer with Xiang-Sha-Liu-Jun-Zi-Tang based on network analysis
por: Jiang, Ke, et al.
Publicado: (2023)

Efficacy of Xiang-Sha-Liu-Jun-Zi on chemotherapy-induced nausea and vomiting: A protocol for systematic review and meta-analysis
por: Xiao, Hang, et al.
Publicado: (2021)

Reversine and herbal Xiang–Sha–Liu–Jun–Zi decoction ameliorate thioacetamide-induced hepatic injury by regulating the RelA/NF-κB/caspase signaling pathway
por: Mai, Zhen-Hao, et al.
Publicado: (2020)

Pharmacokinetic Herb-Drug Interactions of Xiang-Sha-Liu-Jun-Zi-Tang and Paclitaxel in Male Sprague Dawley Rats and Its Influence on Enzyme Kinetics in Human Liver Microsomes
por: Kapelemera, Alinafe Magret, et al.
Publicado: (2022)

The Therapeutic Effect of Traditional LiuJunZi Decoction on Ovalbumin-Induced Asthma in Balb/C Mice
por: Xu, Wenting, et al.
Publicado: (2021)

Network Pharmacology Approach to Investigate the Mechanism of Modified Liu Jun Zi Decoction in the Treatment of Chronic Atrophic Gastritis
por: Zhou, Ming
Publicado: (2022)

Efficacy of modified LiuJunZi decoction on functional dyspepsia of spleen-deficiency and qi-stagnation syndrome: a randomized controlled trial
por: Zhang, Shengsheng, et al.
Publicado: (2013)

Evaluation of the teratogenic effects of three traditional Chinese medicines, Si Jun Zi Tang, Liu Jun Zi Tang and Shenling Baizhu San, during zebrafish pronephros development
por: Ding, Yu-Ju, et al.
Publicado: (2015)

Liu Jun Zi Tang—A Potential, Multi-Herbal Complementary Therapy for Chemotherapy-Induced Neurotoxicity
por: Chiou, Chun-Tang, et al.
Publicado: (2018)

XiangshaLiujunzi decoction alleviates the symptoms of functional dyspepsia by regulating brain–gut axis and production of neuropeptides
por: Liu, Jing, et al.
Publicado: (2015)

Integrating HPLC-Q-TOF-MS/MS, network pharmacology and experimental validation to decipher the chemical substances and mechanism of modified Gui-shao-liu-jun-zi decoction against gastric cancer()
por: Huang, Wenjie, et al.
Publicado: (2023)

The modified Si-Jun-Zi Decoction attenuates colon cancer liver metastasis by increasing macrophage cells
por: Zhou, Jin-Yong, et al.
Publicado: (2019)

Si-Jun-Zi Decoction Treatment Promotes the Restoration of Intestinal Function after Obstruction by Regulating Intestinal Homeostasis
por: Yu, Xiangyang, et al.
Publicado: (2014)

Antitumor Effect of Si-Jun-Zi Decoction on SGC7901 Gastric Cancer Cells by CMTM2 Activation
por: Li, Xiangnan, et al.
Publicado: (2022)

A network pharmacology-based exploration of the active compounds and potential drug targets of Si-Jun-Zi decoction in the treatment of cutaneous squamous cell carcinoma
por: Qin, Si, et al.
Publicado: (2022)

Efficacy and safety of Buzhong Yiqi Decoction in improving cancer-related fatigue and immunity of cervical carcinoma patients: A protocol of randomized controlled trial
por: Hu, Juan, et al.
Publicado: (2021)

Clinical significance of down-regulated HINT2 in hepatocellular carcinoma
por: Zhou, Dong-Kai, et al.
Publicado: (2019)

Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma
por: Zhang, Tao, et al.
Publicado: (2016)

Sha /
por: Vázquez-Figueroa, Alberto
Publicado: (1980)

Prognostic significance of tumor-associated macrophages in patients with nasopharyngeal carcinoma: A meta-analysis
por: Chen, Ya-Lian
Publicado: (2020)

TFEB-associated renal cell carcinoma: A case report and literature review
por: Zhu, Yong, et al.
Publicado: (2022)

Elevated Preoperative Serum Hs-CRP Level as a Prognostic Factor in Patients Who Underwent Resection for Hepatocellular Carcinoma
por: Liu, Yu-Bin, et al.
Publicado: (2015)

Adenoid cystic carcinoma of the gastroesophageal junction: A case report
por: Shou, Chun-Hui, et al.
Publicado: (2019)

A methylomics-associated nomogram predicts the overall survival risk of stage III to IV ovarian cancer
por: Wei, Xuan, et al.
Publicado: (2023)

Network module function enrichment analysis of lung squamous cell carcinoma and lung adenocarcinoma
por: Li, Piaopiao, et al.
Publicado: (2022)

Xiang Zou
por: Zou, Xiang
Publicado: (2022)

Long-Term Outcomes of Nasopharyngeal Carcinoma in 148 Children and Adolescents
por: Lu, Suying, et al.
Publicado: (2016)

Integrated analysis of ceRNA network in hepatocellular carcinoma using bioinformatics analysis
por: Luo, Yu, et al.
Publicado: (2021)

Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): A systematic review and meta-analysis
por: Cui, Kai, et al.
Publicado: (2020)

Squamous cell carcinoma of the cystic duct: A case report and literature review
por: Wang, Hui-Jun, et al.
Publicado: (2023)

Long-Term Follow-Up and Prognostic Factors for Advanced Thymic Carcinoma
por: Wu, Jun-xin, et al.
Publicado: (2014)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Clinicopathological significance of SOX4 and epithelial−mesenchymal transition markers in patients with laryngeal squamous cell carcinoma
por: Zhang, Mingjie, et al.
Publicado: (2021)

Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
por: Chen, Hui Jun, et al.
Publicado: (2021)

Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma
por: Kuo, Hsing-Tao, et al.
Publicado: (2017)

Expression and clinical significance of latent-transforming growth factor beta-binding protein 2 in primary hepatocellular carcinoma
por: Chen, Jinchun, et al.
Publicado: (2019)

Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies
por: Liu, Lin, et al.
Publicado: (2016)

Co-expression of KIAA1199 and hypoxia-inducible factor 1α is a biomarker for an unfavorable prognosis in hepatocellular carcinoma
por: Wang, Dan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l8idaurmk07nvg7b6crg7t4bbs